Sign Up
Stories
CDR-Life's FDA Clearance for Precision Immunotherapy
Share
4D Molecular Therapeutics Raises $300 Mi...
AB-2100 Phase 1/2 Trial Initiated
ADC Therapeutics Reports Financial Progr...
Aadi Bioscience Validates FYARRO® for PE...
Advancing CD70 Targeted Cancer Treatment...
Affini-T Therapeutics at J.P. Morgan Hea...
Overview
API
FDA clears CDR-Life's IND application for precision immunotherapy targeting MAGE-A4 for multiple cancers, including non-small cell lung cancer.
Ask a question
How does this development align with recent advancements in personalized medicine for cancer treatment?
How might the FDA clearance impact the development and availability of precision immunotherapies for solid tumors?
What are the potential implications of off-the-shelf therapies for non-small cell lung cancer and other targeted cancers?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage